Genetics to improve fungal infection treatment
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests if using genetic information can help doctors choose the right dose of the antifungal drug voriconazole. It aims to improve treatment and reduce side effects for people with fungal infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 2 years old or older.
- You have decided to take the medication voriconazole.
- You are admitted to a hospital participating in the trial or can come for regular follow-up visits.
- You have not received a stem cell transplant from a donor without having a DNA sample from before the transplant.
- You are not expected to pass away within the next 7 days.
- You have not been in this trial before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a genetic test to set the first dose of voriconazole (an antifungal medicine) can make treatment safer and more effective for people with blood cancers. It aims to reduce side effects and improve how well the drug works.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This trial tests a new treatment using a patient's own immune cells, called NK cells, that are modified to better fight severe fungal infections that are not responding to standard antifungal medicines. The aim is to see if this approach can help control or clear the infection.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
This trial tests a new way to find infections (using a test called mNGS) that may be quicker and more accurate than standard tests. It is for people with blood cancers who show signs of a possible fungal infection, like fever or abnormal lung scans.
This trial tests whether amphotericin B can treat new fungal infections that develop in people with blood cancers even after they have taken preventive antifungal medicine. It may help patients who have a confirmed or suspected fungal infection while on that prevention.
Hear when a new Fungal Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.